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T
he role of evidence-based medicine in improving 
health  services  and  health  outcomes  is  widely 
recognized in the realm of health care policy.1,2 
However, there is growing recognition, particularly in 
the areas of illicit drug policy and HIV prevention, that 
policy-makers are in many instances implementing sub-
optimal  programs  and  services  because  they  are  not 
basing their decisions on the best available scientific evi-
dence.3–7 The negative impact this has had on the health 
of marginalized groups, including people who use injec-
tion drugs,7 has prompted interest in identifying strat-
egies that can support the implementation of evidence-
based policies.6 
One notable example where a policy-making body has 
failed to use scientific evidence to inform public policy 
is the Canadian federal government’s opposition to Van-
couver’s  supervised  injection  facility,  Insite.  This  op-
position has persisted despite a large body of scientific 
evidence indicating that the program is associated with 
a range of health and social benefits.8,9 The government’s 
position on the supervised injection facility has spurred 
reactions from a broad range of individuals, organiza-
tions and politicians. In particular, two approaches have 
been pursued in an attempt to shift drug policy toward 
an evidence-based approach and maintain the operation 
of this evidence-based health facility. The first approach 
involved knowledge translation (KT), which rests on the 
assumption that the gap between research and policy is 
largely the result of a failure to present research findings 
in terms that are meaningful and accessible to policy-
makers.10,11  However,  when  the  gap  between  research 
and policy is the result of ideological conviction taking 
priority over scientific evidence, as in the case of Insite, 
KT  approaches  do  not  work.  Because  federal  policy-
makers disregarded scientific evidence of the benefits of 
Insite, a second approach was used to support the con-
tinued  operation  of  this  facility:  legal  arguments  and 
proceedings.  We  hope  that  an  overview  of  these  two 
approaches will offer lessons for the implementation of 
evidence-based policies in other areas of health and so-
cial policy and highlight some of the ongoing challenges 
to the application of evidence-based policies in contro-
versial areas.    
The establishment of a supervised injection 
facility in Vancouver, Canada
In the wake of a public health disaster characterized by 
a generalized epidemic of HIV infection among its local 
injection drug user population and high rates of drug-
related overdose deaths, community and public health 
leaders in Vancouver, Canada, established a supervised 
injection facility called Insite.12,13 Insite is a place where 
injection drug users can bring pre-obtained illicit drugs 
and inject in a sterile environment, with clean injecting 
equipment, under the supervision of a nurse.8 In order 
to operate, the injection facility was granted an exemp-
tion from Canada’s Controlled Drugs and Substances Act 
under the premise that it was a medical experiment and 
would undergo extensive evaluation. When it opened in 
2003 the B.C. Centre for Excellence in HIV/AIDS initi-
ated an ongoing and rigorous scientific evaluation to de-
termine whether there was evidence of benefits or harms 
to health and to the community.14,15 In the first five years 
of the scientific evaluation, over 30 studies were pub-
lished in peer-reviewed journals demonstrating that the 
facility was associated with a range of health and social 
benefits  and  not  associated  with  adverse  effects.8  Al-
though this body of evidence would be sufficient to jus-
tify the expansion of just about any other public health program, because of the controversial nature of super-
vised injection facilities, Insite was held to a much higher 
standard and continued to be scrutinized by the federal 
government.9 
Knowledge translation to support an evidence-
based health facility
To  address  this  skepticism,  researchers  involved  in 
Insite’s scientific evaluation developed a multi-pronged 
KT strategy based on findings from the newly emerging 
KT field.10,11,16–18 Health researchers in a range of disci-
plines are increasingly recognizing that generating high-
quality research does not guarantee that the research 
will be used appropriately to inform policy and practice.16 
Within the field of health, efforts are under way to iden-
tify the most effective ways that health research findings 
can be made more accessible, or “translated,” for policy-
makers. Key findings of studies of KT methods are that 
policy-makers  and  community  members  generally  do 
not read academic journals and are more receptive to 
research in the form of plain language summaries and 
synthesis reports.10,11,16,17 As well, although the scientific 
rigour and quality of research is an important determin-
ing factor in the uptake of research findings, KT research 
suggests that even with high-quality research, establish-
ing communication networks between researchers and 
policy-makers is a principal facilitator in the adoption of 
research in public policy.18 Guided by the findings of KT 
research, the researchers involved in Insite’s scientific 
evaluation implemented an extensive KT strategy (see 
Box 1 for highlights of their activities). 
Public opinion polls19 and endorsements by medical 
bodies,20 elected officials21 and police22,23 indicated that 
these KT initiatives were successful and that the evalua-
tion results received widespread acceptance; nonethe-
less, the federal government remained fiercely opposed 
to  the  program,  refusing  to  grant  Insite  a  three-year 
extension for its operation and imposing a moratorium 
on trials of safer injection facilities in other Canadian 
cities.9 It became evident that the basis of its opposition 
was ideological, that scientific evidence was irrelevant in 
this policy environment,24 and that KT was not equipped 
to overcome the systematic disregard of scientific evi-
dence by the federal government.9 
Legal arguments and proceedings to support an 
evidence-based health facility
To prevent the federal government from closing the facil-
ity, in 2007 two community-based non-profit organiza-
tions representing the interests of injection drug users, 
along with two individual plaintiffs, sought legal advice. 
Box 1: Highlights of knowledge translation activities  
supporting evidence-based policies and the continued  
operation of Insite, Vancouver’s supervised injection facility1
Media engagement
•	 Educated	media	about	research	findings	through	media	briefs
•	 Participated	in	hundreds	of	media	interviews	
•	 Wrote	letters	to	the	editor,	op-eds	and	commentaries	for	
newspapers	and	magazines
Plain language summaries
•	 Synthesized	research	into	reader-friendly	summaries	(both	long	and	
short	versions)
•	 Distributed	summaries	to	policy-makers	and	other	stakeholders,	
including	a	summary	report	sent	to	all	federal	members	of	
Parliament
Oral presentations
•	 Delivered	dozens	of	presentations	to	a	wide	range	of	audiences,	
including	the	Canadian	parliament;	provincial	and	municipal	policy-
makers	and	advisers;	health	care	providers;	community	groups,	
including	Insite’s	local	community;	and	the	general	public
Internet
•	 Developed	a	webpage	dedicated	to	posting	research	findings	and	
plain	language	summaries	(see	the	Urban	Health	Research	Initiative	
website)
Political commentaries in academic journals
•	 Published	multiple	commentaries	describing	the	political	situation	
around	the	evaluation	of	the	supervised	injection	facility	and	the	
disregard	of	scientific	evidence	by	the	Canadian	government	6,9,28–33
				1	These	knowledge	translation	activities	were	conducted	primarily	
by	the	principal	investigators	of	the	scientific	evaluation	of	Insite,		
Drs	Thomas	Kerr	and	Evan	Wood.	
Relying on a range of legal arguments, this group launched 
a lawsuit against the Attorney General of Canada and the 
Minister of Health.25 One of the primary arguments in the 
case was that people who use injection drugs have a con-
stitutional right to access Insite because of its importance 
as a health care service that reduces the harms of injec-
tion drug use. Another argument was based on the doc-
trine of interjurisdictional immunity. Specifically, given 
that the province has constitutional power with respect to 
health care, and because Insite is a health care service, the 
facility falls under the jurisdiction of the provincial gov-
ernment and its operation should not be subject to federal 
interference.25 In the process of the court case, KT again 
came into play when researchers were asked to present 
their findings in the form of sworn affidavits.
After lengthy proceedings, in May 2008 the B.C. Su-
preme Court dismissed the plaintiffs’ claims that inter-
jurisdictional  immunity  applied,  but  it  ruled  that  the 
current  Controlled  Drugs  and  Substances  Act,  to  the 
extent that it provides the federal government with the 
power to close the facility, is in violation of the Canadian 
Charter of Rights and Freedoms,26 and the government 
was ordered to amend the relevant sections of the Con-
trolled Drugs and Substances Act to allow Insite to con-
tinue operating. This decision represented an important 
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step  forward  for  evidence-based  drug  policy,  and  the 
courts  effectively  became  an  arena  where  scientific 
evidence  and  constitutional  rights  trumped  ideology. 
Although  the  ruling  was  not  directly  concerned  with 
implementing evidence-based drug policy, the decision 
hinged on scientific evidence to establish that the pro-
gram offered health benefits to injection drug users. It 
is undeniable that the  B.C. Supreme Court decision has 
already had a significant impact on the course of Insite’s 
history and prevented its imminent closure; however, 
the power of the ruling and its implications for the sus-
tained advancement of evidence-based drug policy re-
main uncertain.  
One reason for this uncertainty is that Charter rights 
have limitations, some of which are embedded in the 
Charter itself. Specifically, section 1 allows Parliament 
and provincial legislatures to limit Charter rights if the 
limitation can be “demonstrably justified in a free and 
democratic society.” Furthermore, Parliament and prov-
incial legislatures can use the notwithstanding clause 
provided by section 33 to override Charter protections 
for limited periods of time. Although these provisions 
are  rarely  used  to  reverse  judicial  rulings,  legislative 
bodies have invoked sections 1 and 33 (Ford v. Quebec, 
[1988] 2 S.C.R. 712; R. v. Daviault, [1994] 3 S.C.R. 63). 
Another source of uncertainty regarding the B.C. Su-
preme Court decision is that court rulings can be over-
turned. Immediately after the 2008 court decision the 
government  appealed  the  ruling  that  sections  of  the 
Controlled  Drugs  and  Substances  Act  violated  Char-
ter rights. Conversely, the plaintiffs in the original case 
cross-appealed  the  dismissal  of  the  interjurisdictional 
immunity claim. In January 2010 justices from the B.C. 
Supreme Court of Appeals ruled in a 2–1 majority that 
the doctrine of interjurisdictional immunity did indeed 
apply in the case; the implication of this ruling was that 
the Controlled Drugs and Substances Act could not inter-
fere with the operations of Insite or hinder its ability to 
provide health care to people who inject drugs. Although 
the ruling in favour of applying the doctrine of interjuris-
dictional immunity made a ruling on the Charter issue 
unnecessary, the justices provided their assessment of 
the arguments pertaining to this aspect of the case. With 
the same 2–1 majority, the justices concluded that the 
original ruling on the Charter issue was correct and that 
aspects of the Controlled Drugs and Substances Act were 
unconstitutional.27 Despite the positive implications of 
the rulings from the B.C. Supreme Court of Appeals on 
Insite’s continued operation, in February of this year the 
federal government announced that it would appeal this 
decision to the Supreme Court of Canada.21   
Conclusion
Clearly,  implementing  evidence-based  policies  can  be 
particularly  challenging  in  some  environments.  Al-
though gaps between science and policy may at times be 
the result of a lack of communication between research-
ers and decision-makers, there are other instances where 
understanding scientific data is not the barrier to its use. 
In these cases other avenues will need to be pursued, and 
legal proceedings offer potential in this area. However, 
there are challenges involved in legal proceedings, in-
cluding uncertainty regarding the impact and meaning 
of a ruling owing to its potential to be challenged and re-
versed. The case of the supervised injection facility illus-
trates that although legal proceedings are a potentially 
promising  vehicle  for  advancing  evidence-based  drug 
policy, as with KT efforts, there are no guarantees that 
such approaches can effect substantial change. Never-
theless,  given  the  health  and  social  harms  resulting 
from persistent gaps between evidence and practice in 
the areas of illicit drug policy and HIV prevention,7 ac-
tions to support even incremental advancements must 
be pursued. 
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